Is there evidence to support the use of direct Factor Xa inhibitors in coronary artery disease?

Reviews on Recent Clinical Trials

Volumn 6, Issue 2, 2011, Pages 147-157

  Doggrell, Sheila Anne ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Apixaban; Clinical pharmacology; Clinical trials; Coronary artery disease; DX 9065a; Otamixaban; Preclinical pharmacology; Rivaroxaban; ZK 807834

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ACETYLSALICYLIC ACID; ALTEPLASE; ANTIVITAMIN K; APIXABAN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DANAPAROID; EDOXABAN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIDEXABAN; FONDAPARINUX; FXV 673; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; N ETHYL N [4 (4 PIPERIDINYL)BUTYRYL]GLYCYLASPARTYL 3 CYCLOHEXYLALANINAMIDE; OTAMIXABAN; PLACEBO; PRASUGREL; RAZAXABAN; RIVAROXABAN; RPR 130673; TIROFIBAN; UNCLASSIFIED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOT LYSIS; CORONARY ARTERY DISEASE; CORONARY STENT; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; GINGIVA BLEEDING; HEART INFARCTION; HEMATOMA; HIP ARTHROPLASTY; HUMAN; INJECTION SITE CONTUSION; KNEE ARTHROPLASTY; LOADING DRUG DOSE; LOW DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTHROMBIN TIME; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; TASTE DISORDER; THROMBIN TIME; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM;

AMIDINES; CORONARY ARTERY DISEASE; CYCLIC N-OXIDES; FACTOR XA; HUMANS; MORPHOLINES; NAPHTHALENES; PROPIONIC ACIDS; PYRAZOLES; PYRIDINES; PYRIDONES; THIOPHENES;

EID: 79953838461     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488711795177921     Document Type: Article

References (65)

1. Wong GC, Giugliano RP, Antman EM. Use of low-molecularweight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 2003; 289: 331-42.
2. Daiichi Sankyo Co., Ltd: Priority Development Projects (accessed 15.1.2010). Available from: http://www.daiichisankyo.com/rd/project/ index.html
3. Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994; 71: 314-9.
4. Morishima Y, Tanabe K, Terada U, Hara T, Kunitada S. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thrombo Haemost 1997; 78: 1366-71.
5. Murayama N, Tanaka M, Kunitada S, et al. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clin Pharmacol Ther 1999; 66: 258-64.
6. Simbo D, Osende J, Chen J, et al. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Thromb Haemost 2002; 88: 733-8.
7. Dyke CK, Becker RC, Kleiman NS, et al. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 2002; 105: 2385-91.
8. Becker RC, Alexander JH, Dyke C, et al. XaNADU-1B Investigators. Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. Thromb Res 2006; 117: 439-46.
9. Alexander JH, Dyke CK, Yang H, et al. XaNADU-PCI PILOT Investigators. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. J Thromb Haemost 2004; 2: 234-41.
10. Alexander JH, Yang H, Becker RC, et al. XaNADU-ACS trial. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS trial. J Thromb Haesmost 2005; 3: 439-47.
11. Phillips GB, Buckman BO, Davey DD, et al. Discovery of N-[2-[5-Amino(imino)methyl]-2-hydroxyphenoxy]-3,5-difluoro-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridine-4-yl]-N methylglycine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa. J Med Chem 1998; 41: 3557-62.
12. Zafar MU, Farkouh ME, Osende J, et al. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients. Thromb Haemost 2007; 97: 485-92.
13. Post JM, Sullivan ME, Abendschein D, Ewing J, Hinchman JW, Light DR. Human in vitro pharmacodynamic profile of the selective Factor Xa inhibitor ZK-807834 (CI-1031). Thromb Res 2002; 105: 347-52.
14. Abendschein DR, Baum PK, Martin DJ, et al. Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits. J Cardiovasc Pharmacol 2000; 35: 796-805.
15. McClanahan TB, Hicks GW, Morrison AL, et al The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis. Eur J Pharmacol 2001; 432: 187-94.
16. Abendschein DR, Braum PK, Verhallen P, Eisenberg PR, Sullivan ME, Light DR. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs. J Pharmacol Exp Ther 2001; 296: 567-72.
17. nd, Miller RS, et al. Inhibition and reversal of platelet-rich arterial thrombus in vivo: direct vs indirect factor Xa inhibition. J Thromb Haemost 2004; 2: 2162-9.
18. Chu V, Brown K, Colussi D, et al. Pharmacological characterization of a novel factor Xa inhibitor, FXV673. Thromb Res 2001; 103: 309-24.
19. Rebello SS, Kasiewski CJ, Wang W, et al. Role of short-term inhibition of factor Xa by FXV673 in arterial passivation: a study in a chronic model of thrombosis in conscious dogs. J Cardiovasc Pharmacol 2001; 38:299-97
20. Rebello SS, Bentley RG, Morgan SR, et al. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombosis. Br J Pharmacol 2001; 133: 1190-8.
21. Paccaly A, Ozoux ML, Chu V, et al. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor. Thromb Haemost 2005; 94; 1156-1163.
22. Paccaly A, Frick A, Rohatagi S, et al. Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure. J Clin Pharmacol 2006; 46: 37-44.
23. Hinder M, Frick A, Rosenburg R, et al. Anti-coagulant and antiplatelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid. Thromb Haemost 2006; 95:224-8.
24. Hinder M, Paccaly A, Frick A, et al. Anticoagulant and antiplatelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofibran in healthy volunteers. Thromb Haemost 2005; 93: 794-5.
25. Hinder M, Frick A, Jordaan P, et al. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. Clin Pharmacol Ther 2006; 80: 691-702.
26. Cohen M, Bhatt DL, Alexander JH, et al. Randomized, doubleblind, dose-ranging study of otamixaban, a novel, parenteral, shortacting direct factor Xa inhibitor, in percutaneous coronary intervention-The SEPIA-PCI trial. Circulation 2007; 115: 2642-51.
27. Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-AC1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009; 374: 787-95.
28. Otamixaban (Accessed 10/22010) Available from http://clinicaltrials.gov/ct2/results?term=otamixaban
29. /-dimethylaminomethy)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly, potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem 2005; 48: 1729-44.
30. New advances in thrombosis help further understanding of disease prevention (Accessed 19/1/2010) Available from: http://www.medicalnewstoday.com/articles/4814.php
31. Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007; 50: 5339-56.
32. Jiang X, Crain EJ, Luettgen JM, Schumacher WA, Wong PC. Apixaban, an oral direct factor Xa inhibitor, inhibits human clotbound factor Xa activity in vitro. Thromb Haemost 2009; 101: 780-2.
33. Wong PC, Crain Ej, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008; 6: 820-9.
34. Wong PC, Watson CA, Crain EJ. Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost 2008; 6: 1736-41.
35. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010; 38(3): 448-58.
36. Raghavan N, Forst CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37: 74-81.
37. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thrombolysis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-75.
38. Botticelli Investigators, the writing committee, Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factore Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6:1313-8.
39. APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119: 2877-85.
40. Phase III Acute Coronary Syndrome (APPRAISE-2). (Accessed 19/1/2010) Available at: http://clinicaltrials.gov/ct2/show/ NCT00831441?term=apixaban&rank=16
41. Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithromboin agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005; 48: 5900-8.
42. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral direct factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-21.
43. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 37: 1056-64.
44. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-21.
45. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-80.
46. Turpie AG, Fisher WD, Bauer KA, et al. For the ODIXa-knee study group. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism. A phase II doseranging study. J Thromb Haemost 2005; 3: 2479-86.
47. Lassen MR, Ageno W, Borris LC, et al. RECORD3 investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee anthroplasty. N Engl J Med 2008; 358: 2776-86.
48. Turpie AG, Lassen MR, Davidson BL, et al. RECORD 4 investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373:1673-80.
49. Eriksson BI, Borris L, Dahl OE, et al. And ODIXa-HIP Study Investigators. Oral, direct, Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip re placement. J Thromb Haemost 2006; 4: 121-8.
50. Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-for the prevention of thromboembolism in patients undergoing total hip replacement. Thromb Res 2007; 120: 685-93.
51. Eriksson BI, Borris LC, Friedman RJ, et al. For the RECORD1 study group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358:2765-75.
52. Kakar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. RECORD2 Investigators. Lancet 2008; 372: 31-9.
53. Agnelli G, Gallus A, Goldhaber SZ, et al. ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116: 180-7.
54. Buller HR, Lensing AWA, Prins MH, et al. on behalf of the Einstein-DVT Dose-Ranging Study Investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008; 112: 2242-7.
55. Mega JL, Braunwald E, Mohanavelu S, et al. ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46); a randomised, double-blind, phase II trial. Lancet 2009; 374: 29-38.
56. Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007; 47:1398-407.
57. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-and oral, direct factor Xa inhibitor-are not affected by aspirin. J Clin Pharmacol 2006; 46: 981-90.
58. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007; 47: 218-26.
59. An efficacy and safety study for rivaroxaban in patients with acute coronary syndrome. (Accessed 20/1/2010) Available at: http://clinicaltrials.gov/ct2/show/NCT00809965?term=RIVAROX ABAN+CORONARY&rank=2
60. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45-54.
61. Blazing MA, de Lemos JA, White HD, et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-STsegment elevation acute coronary syndromes who receive tirofibran and aspirin: a randomized controlled trial. JAMA 2004; 292: 55-64.
62. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216.
63. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1454-1476.
64. Gurm HS, Eagle K. Rivaroxaban in acute coronary syndromes: too soon to know. Lancet 2009; 374: 3-4.
65. AVERROES: Apixaban yields significant reductions in stroke, no increased bleeding (Accessed 14/9/2010 Available from: http://www.theheart.org/article/1087291/print.do